Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
29.16
Dollar change
+0.05
Percentage change
0.17
%
Index- P/E30.32 EPS (ttm)0.96 Insider Own0.00% Shs Outstand653.30M Perf Week3.29%
Market Cap19.05B Forward P/E19.08 EPS next Y1.53 Insider Trans- Shs Float653.30M Perf Month5.54%
Income633.85M PEG2.26 EPS next Q0.17 Inst Own7.15% Short Float0.31% Perf Quarter-5.94%
Sales2.39B P/S7.97 EPS this Y20.63% Inst Trans24.47% Short Ratio3.27 Perf Half Y-21.93%
Book/sh7.17 P/B4.07 EPS next Y32.92% ROA13.24% Short Interest2.05M Perf Year-23.22%
Cash/sh6.38 P/C4.57 EPS next 5Y13.40% ROE14.70% 52W Range26.32 - 42.99 Perf YTD-8.42%
Dividend Est.- P/FCF18.84 EPS past 5Y20.52% ROI13.25% 52W High-32.18% Beta0.92
Dividend TTM- Quick Ratio13.32 Sales past 5Y43.21% Gross Margin- 52W Low10.79% ATR (14)0.67
Dividend Ex-Date- Current Ratio13.34 EPS Y/Y TTM-17.62% Oper. Margin32.33% RSI (14)54.32 Volatility1.17% 1.84%
Employees2204 Debt/Eq0.02 Sales Y/Y TTM17.14% Profit Margin26.50% Recom2.07 Target Price36.80
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q15.29% Payout0.00% Rel Volume1.06 Prev Close29.11
Sales Surprise0.62% EPS Surprise-55.49% Sales Q/Q-5.89% EarningsFeb 14 AMC Avg Volume627.49K Price29.16
SMA203.99% SMA50-2.02% SMA200-15.88% Trades Volume663,123 Change0.17%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Upgrade BMO Capital Markets Market Perform → Outperform $46 → $48
Jan-22-24Downgrade Citigroup Neutral → Sell
Dec-06-23Upgrade UBS Neutral → Buy
Nov-10-23Upgrade Deutsche Bank Hold → Buy
Nov-08-23Upgrade DNB Markets Sell → Buy
Oct-18-23Initiated Exane BNP Paribas Underperform
Sep-06-23Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23Initiated BTIG Research Buy $44
Jul-14-23Initiated HSBC Securities Buy
May-31-23Initiated UBS Neutral
Feb-23-24 05:50PM
05:35PM
Feb-19-24 04:40AM
Feb-15-24 06:00AM
Feb-14-24 02:09PM
11:41AM Loading…
11:41AM
11:02AM
Feb-02-24 06:45AM
Jan-25-24 02:22PM
Jan-23-24 06:24AM
Jan-22-24 06:40PM
Jan-19-24 09:55AM
Jan-09-24 06:45AM
06:45AM
Jan-03-24 12:55AM
09:52AM Loading…
Jan-02-24 09:52AM
Dec-12-23 07:00AM
Dec-09-23 12:00PM
12:00PM
Dec-05-23 05:26PM
Nov-27-23 07:00AM
Nov-21-23 04:45PM
04:42PM
Nov-09-23 09:14AM
05:00AM
Nov-08-23 05:39PM
11:09AM
Nov-07-23 11:01AM
Nov-02-23 09:05AM
Oct-22-23 10:30AM
06:22AM Loading…
Oct-17-23 06:22AM
Sep-28-23 02:38PM
Sep-25-23 07:45AM
05:55AM
05:55AM
Sep-12-23 02:04PM
Sep-04-23 03:00PM
03:00PM
Aug-28-23 10:06AM
Aug-24-23 09:57AM
Aug-15-23 01:09PM
Aug-03-23 11:01AM
Jul-27-23 06:01PM
Jul-21-23 04:30AM
Jul-20-23 06:22AM
Jun-27-23 06:50PM
Jun-22-23 07:00AM
Jun-20-23 02:45PM
Jun-09-23 03:01AM
Jun-08-23 05:22PM
Jun-06-23 02:00AM
Jun-01-23 03:40PM
May-31-23 08:15AM
May-25-23 05:10PM
May-23-23 03:14PM
May-19-23 12:38PM
May-10-23 11:01AM
Apr-24-23 04:39AM
Apr-20-23 07:45PM
Apr-18-23 06:25AM
03:37AM
Apr-17-23 03:43PM
02:00AM
Apr-06-23 04:33PM
Apr-03-23 04:30PM
10:12AM
Mar-29-23 04:19PM
04:10PM
09:54AM
Mar-28-23 02:00AM
Mar-27-23 09:00AM
Mar-20-23 10:21AM
Mar-13-23 09:41AM
Mar-06-23 10:08AM
Feb-28-23 02:54PM
Feb-27-23 11:21AM
Feb-24-23 03:36PM
03:33PM
Feb-23-23 06:00AM
Feb-22-23 03:45PM
01:12PM
11:12AM
11:01AM
Jan-24-23 02:00PM
06:27AM
Jan-23-23 11:40AM
Jan-20-23 07:04AM
Jan-19-23 11:00AM
Jan-03-23 12:31PM
Jan-02-23 07:56AM
Dec-21-22 07:00AM
Dec-14-22 03:20PM
Dec-13-22 03:52PM
03:05PM
02:58PM
11:40AM
10:05AM
Dec-12-22 09:40AM
08:23AM
Dec-11-22 05:30PM
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.